ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101

Also written as “TJ101”, “TJ101 injection Test Product” and “TJ101 injection Reference Product”.

Its studies are mostly in Lung Neoplasms, led by 2 companies.

Drug pageAnti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 12, 20203 company-led studies, 1 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TJ Biopharmaits history only20 open or runningphase 3since Nov 12, 2020Nov 12, 2020none ahead
Phrontline Biopharmaits history only11 open or runningphase 1since Sep 1, 2025Sep 1, 2025Dec 30, 2026phase 1 · NCT07181473

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 12, 2020First study: phase 3 study in Pediatric Growth Hormone DeficiencyNew to TJ BiopharmaTJ Biopharma · NCT04633057 · 168 enrolled · China
  2. Sep 1, 2025Phrontline Biopharma’s first study: phase 1 study in Lung NeoplasmsNew to Phrontline BiopharmaPhrontline Biopharma · NCT07181473 · 200 planned · United States, China
  3. Dec 10, 2025Phase 1 study in Healthy Adult Males in ChinaTJ Biopharma · NCT07300436 · 96 enrolled · China

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in Lung NeoplasmsPhrontline Biopharma · NCT07181473

TargetBeta

CD276 →EGFR →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) bispecific antibody directed against the tumor associated antigens (TAAs) human epidermal growth factor receptor (EGFR) and B7-homologue 3 (B7-H3, CD276) ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07300436Healthy Adult Males in China · China1CompletedTJ BiopharmaMar 16, 202696
NCT07181473Lung Neoplasms · United States, China1RecruitingPhrontline BiopharmaDec 30, 2026200
NCT04633057Pediatric Growth Hormone Deficiency · China3CompletedTJ BiopharmaJul 31, 2023168

How it is read

Names in the registry

  • “TJ101”, 2 entries
  • “TJ101 injection Test Product”, 1 entry
  • “TJ101 injection Reference Product”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.